Lee Mozessohn

613 total citations
50 papers, 363 citations indexed

About

Lee Mozessohn is a scholar working on Oncology, Genetics and Geriatrics and Gerontology. According to data from OpenAlex, Lee Mozessohn has authored 50 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Genetics and 10 papers in Geriatrics and Gerontology. Recurrent topics in Lee Mozessohn's work include Acute Myeloid Leukemia Research (10 papers), Frailty in Older Adults (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Lee Mozessohn is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Frailty in Older Adults (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Lee Mozessohn collaborates with scholars based in Canada, United States and Australia. Lee Mozessohn's co-authors include Kelvin Chan, Jordan J. Feld, Lisa K. Hicks, Matthew C. Cheung, Rena Buckstein, Gregory A. Abel, Craig C. Earle, Chenthila Nagamuthu, Clark DuMontier and Liying Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Lee Mozessohn

39 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lee Mozessohn Canada 10 93 93 74 67 67 50 363
Naimish Pandya United States 10 226 2.4× 80 0.9× 38 0.5× 24 0.4× 34 0.5× 20 473
HH Hansen Denmark 6 247 2.7× 149 1.6× 36 0.5× 21 0.3× 41 0.6× 10 514
Stefanie Hieke Germany 9 250 2.7× 66 0.7× 51 0.7× 47 0.7× 290 4.3× 18 572
Erica Linden United States 8 116 1.2× 46 0.5× 101 1.4× 36 0.5× 129 1.9× 12 374
Neeta K. Venepalli United States 11 84 0.9× 75 0.8× 33 0.4× 16 0.2× 19 0.3× 33 434
Franklin Hendrick United States 10 80 0.9× 42 0.5× 31 0.4× 106 1.6× 156 2.3× 20 367
Marika Rasschaert Belgium 12 261 2.8× 28 0.3× 84 1.1× 51 0.8× 36 0.5× 32 545
Christophe Desauw France 8 305 3.3× 41 0.4× 50 0.7× 14 0.2× 14 0.2× 27 603
Ignazio Carreca Italy 12 372 4.0× 56 0.6× 76 1.0× 9 0.1× 24 0.4× 35 722
C. G. Schaar Netherlands 10 159 1.7× 40 0.4× 43 0.6× 34 0.5× 148 2.2× 18 413

Countries citing papers authored by Lee Mozessohn

Since Specialization
Citations

This map shows the geographic impact of Lee Mozessohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee Mozessohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee Mozessohn more than expected).

Fields of papers citing papers by Lee Mozessohn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee Mozessohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee Mozessohn. The network helps show where Lee Mozessohn may publish in the future.

Co-authorship network of co-authors of Lee Mozessohn

This figure shows the co-authorship network connecting the top 25 collaborators of Lee Mozessohn. A scholar is included among the top collaborators of Lee Mozessohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee Mozessohn. Lee Mozessohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gong, Inna Y., Michael Crump, Anca Prica, et al.. (2025). Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis. PubMed. 2(3). 100117–100117.
2.
Mozessohn, Lee, et al.. (2025). Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency. British Journal of Clinical Pharmacology. 91(5). 1511–1515.
3.
Buckstein, Rena, Jeannie Callum, Anca Prica, et al.. (2024). Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE. Transfusion. 64(2). 223–235. 1 indexed citations
4.
Arya, Sumedha, Lee Mozessohn, Inna Y. Gong, et al.. (2024). The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study. Leukemia & lymphoma. 65(5). 629–637. 2 indexed citations
6.
7.
Gong, Inna Y., Michael Crump, Anca Prica, et al.. (2024). Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis. Blood. 144(Supplement 1). 3092–3092.
8.
Mozessohn, Lee, David Sanford, Kristjan Paulson, et al.. (2024). Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists. Annals of Hematology. 103(12). 5371–5376.
9.
Mozessohn, Lee, Ning Liu, Brian Leber, et al.. (2023). Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice. 19(4). e559–e569. 3 indexed citations
10.
Ravindran, Mithunan, et al.. (2023). A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML. Blood Advances. 8(3). 629–639. 1 indexed citations
11.
Tramontano, Angela C., Lee Mozessohn, Ann S. LaCasce, et al.. (2023). Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study. The Lancet Haematology. 10(7). e530–e538. 11 indexed citations
12.
Gong, Inna Y., Kelvin Chan, Lorraine L. Lipscombe, Matthew C. Cheung, & Lee Mozessohn. (2023). Fracture risk among patients with cancer compared to individuals without cancer: a population-based study. British Journal of Cancer. 129(4). 665–671. 5 indexed citations
13.
Hshieh, Tammy T., Clark DuMontier, Chelsea E. Hawley, et al.. (2021). Impact of Polypharmacy and Potentially Inappropriate Medications Among Older Adults with Blood Cancers. Blood. 138(Supplement 1). 4089–4089. 2 indexed citations
14.
DuMontier, Clark, Hajime Uno, Tammy T. Hshieh, et al.. (2021). Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica. 107(5). 1172–1180. 38 indexed citations
15.
Mozessohn, Lee, Liying Zhang, Oreofe O. Odejide, et al.. (2021). Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leukemia & lymphoma. 62(12). 2882–2889.
16.
Abel, Gregory A., Hajime Uno, Zilu Zhang, et al.. (2019). Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial. Blood. 134(Supplement_1). 67–67. 4 indexed citations
17.
Mozessohn, Lee, Craig C. Earle, David Spaner, et al.. (2016). The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. JNCI Journal of the National Cancer Institute. 109(3). djw226–djw226. 22 indexed citations
18.
Mozessohn, Lee, et al.. (2014). Management of Severe Dabigatran-Related Hemorrhage: Case Report, Considerations for Management, and Recommendations. The Canadian Journal of Hospital Pharmacy. 67(1). 43–7. 5 indexed citations
19.
Chan, Kelvin, Eric Siu, Lee Mozessohn, & Matthew C. Cheung. (2013). Publication Patterns of Cancer Cost-Effectiveness Studies Presented at Major Conferences. Current Oncology. 20(6). 319–325. 5 indexed citations
20.
Mozessohn, Lee, Matthew C. Cheung, Michael Crump, et al.. (2011). Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis. Blood. 118(21). 4981–4981. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026